Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients

Zekri, Abdel‐Rahman N.; Bakr, Yasser Mabrouk; Ezzat, Maali Mohamed; Zakaria, Mohamed Serag Eldeen; Elbaz, Tamer

doi:10.7314/apjcp.2015.16.16.6923

Cited by 17 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In subsequent screening steps for remained articles, eight papers were excluded due to insufficient information. Consequently, 25 articles with 27 studies including 2,693 patients with cancer and 3,040 healthy controls were included in meta‐analysis for pooling SMD analysis (Assiri, Kamel, & Hassanien, ; Chen et al, ; Chen et al, ;; Dalamaga et al, ; El‐Benhawy, El Moneim, & Ebeid, ; Fazeli et al, , ; Gąsiorowska et al, ; Ilhan et al, ; Li et al, ; Lu, Wang, Xia, & Qian, ; Luhn et al, ; Nakajima et al, , , ; Nergiz Avcioglu et al, ; Rodrigo et al, ; Suga et al, ; Sun et al, ; Tian et al, ; Tsai et al, ; Tulubas, Mete, Oznur, & Topcu, ; Yu‐Duan et al, ; Zekri, Bakr, Ezzat, Zakaria, & Elbaz, ; Zhang et al, ). Of these, 12 publications with 14 studies, provided data for ORs, were also included in our secondary meta‐analysis to estimate pooled ORs with 95% CIs (Assiri et al, ; Chen et al, ; Chen et al, ; El‐Benhawy et al, ; Luhn et al, ; Nakajima et al, , , ; Rodrigo et al, ; Tian et al, ; Tsai et al, ; Yu‐Duan et al, ).…”

Section: Resultsmentioning

confidence: 99%

Circulating visfatin levels and cancers risk: A systematic review and meta‐analysis

Mohammadi

Mianabadi

Mehrad‐Majd

2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Visfatin levels have been reported to be abnormal in many types of cancers. However, epidemiological studies yielded inconsistent results. Therefore, a meta-analysis was performed to assess the association between circulating visfatin levels and cancer risk. A systematic search was conducted for relevant studies in health-related electronic databases up to March 2018. Data related to standard mean difference (SMD) and overall odds ratio (ORS) were collected and analyzed. Summary SMD and pooled OR with 95% CIs were calculated using a random-effect model. Funnel plot and Egger's linear regression test were conducted to examine the risk of publication bias. A total of 27 studies with 2,693 cases and 3,040 healthy controls were included in meta-analysis for pooling SMD analysis. The results of the meta-analysis showed a significant higher visfatin levels in patients with various cancers than in controls, with a pooled SMD of 0.88, 95% CI = 0.56-1.20, p = 0.000. In subgroup, metaregression, Galbraith plot, and sensitivity analysis showed no substantial difference among all the analyzed factors. Data from 14 studies were also used for pooling ORs analysis.

show abstract

Section: Resultsmentioning

confidence: 99%

Circulating visfatin levels and cancers risk: A systematic review and meta‐analysis

Mohammadi

Mianabadi

Mehrad‐Majd

2018

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Further, after full-text reviewing, 13 papers were excluded as they failed to meet our predefined inclusion criteria, leaving 31 eligible papers for meta-analysis in this study. 5 – 13 , 22 – 43 Thereof, 16 papers provided data by cancer type, gender or race, and so there were 48 qualified studies.…”

Section: Resultsmentioning

confidence: 99%

“… 6 – 8 By contrast, other researchers failed to confirm this claim, 9 – 11 and some of them even found a higher concentration of circulating total adiponectin in patients with colorectal cancer than in controls. 12 , 13 Several systematic reviews and meta-analyses have summarized published data involving the association between circulating total adiponectin and colorectal cancer risk, 14 – 20 while interpretation of pooled findings in most cases is clouded by the presence of substantial heterogeneity and none considered adiponectin fractions as separate factors. With growing epidemiological data, our understanding on circulating adiponectin and its fractions and colorectal cancer needs replenishment and renewal.…”

Section: Introductionmentioning

confidence: 99%

Low circulating total adiponectin, especially its non-high-molecular weight fraction, represents a promising risk factor for colorectal cancer: a meta-analysis

Lü¹,

Huang²,

Li³

et al. 2018

OTT

View full text Add to dashboard Cite

AimThe principal goal of this meta-analysis is to test the hypothesis that circulating total adiponectin or certain fractions may represent a promising biological candidate in modulating the risk of colorectal cancer.MethodsThe processes of paper identification, paper selection and data extraction were accomplished independently by two authors. Effect-size estimates were expressed as weighted mean difference (WMD) and 95% confidence interval (95% CI). A total of 31 papers including 48 qualified studies (7,554 patients with colorectal cancer and 9,798 controls) were meta-analyzed.ResultsPooling all studies found that circulating total adiponectin was significantly lower in patients with colorectal cancer than in controls (WMD: −0.76 µg/mL, 95% CI: −1.20 to −0.32, p=0.001), with significant heterogeneity (I2: 94.2%) and low publication bias (Egger’s p=0.336). By adiponectin fractions, the difference in high-molecular weight (HMW) adiponectin was comparable between the two groups (WMD: −0.22 µg/mL, 95% CI: −0.70 to 0.25, p=0.350), while non-HMW adiponectin was significantly lower in patients with colorectal cancer than in controls (WMD: −0.27 µg/mL, 95% CI: −0.35 to −0.19, p<0.001), with marginal heterogeneity (I2: 52.3%). Subgroup analysis revealed that effect-size estimates were heterogeneous when grouping studies by cancer subtype, region, study design, matching status, gender and obesity. Further meta-regression analysis indicated that age and gender were significant potential sources of heterogeneity. The results showed the studied subgroups were not subject to publication bias (Egger’s p<0.1).ConclusionOur data collectively indicate that low circulating total adiponectin, especially its non-HMW fraction, represents a promising risk factor for colorectal cancer. Further studies are needed to explore underlying mechanisms.

show abstract

“…Some studies have shown acceptable diagnostic value on the part of circulating visfatin levels for the detection of early CRC (sensitivity= 68.2% and specificity=70.8%, AUC=0.812)[32] and postmenopausal breast cancer (sensitivity= 97.6% and specificity=92.6%, AUC=0.724)[33]. To our knowledge, this is the first study to investigate the potential diagnostic value of serum visfatin levels for HCC.…”

Section: Discussionmentioning

confidence: 99%

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma

Sun

Zhu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Visfatin is considered a pro-inflammatory adipocytokine, and it is commonly increased in obesity-related diseases. This study aimed to evaluate the levels of serum visfatin in patients with hepatocellular carcinoma (HCC) and its diagnostic and predictive value in detecting HCC. Fasting serum levels of visfatin of 135 HCC patients, 115 chronic hepatitis B (CHB) patients, 129 liver cirrhosis (LC) patients, and 149 healthy controls were determined via enzyme-linked immunosorbent assay. Meanwhile, serum alpha fetal protein (AFP) and interleukin-6 (IL-6) were also assayed. The median serum visfatin concentration in HCC patients was 1.113 ng/ mL (range: 0.823-2.214 ng/mL), which was significant higher than those of healthy controls, CHB patients, and LC patients (P<0.05). The serum visfatin concentration in HCC patients was positively correlated with AFP (r=0.595, P<0.001) and IL-6 (r=0.261, P<0.015) and was also associated with tumor size and tumor node metastasis stage. Moreover, elevated levels of serum visfatin were associated with a higher HCC risk for CHB and LC patients. Multivariate Cox regression analysis had shown that HCC patients with high levels of serum visfatin had significantly shorter overall survival times than those with low serum visfatin levels (P<0.001). Using a cutoff visfatin level of 1.403 ng/mL, the receiver operating characteristic curve analysis showed unappealing sensitivity and specificity values (45.76% and 74.79%, respectively; AUC=0.626) regarding visfatin's use as a diagnostic marker for HCC. Our results indicate that increased serum visfatin levels are associated with poor prognosis of HCC. Visfatin may be a potential therapeutic target of HCC.

show abstract

Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients

Cited by 17 publications

References 28 publications

Circulating visfatin levels and cancers risk: A systematic review and meta‐analysis

Circulating visfatin levels and cancers risk: A systematic review and meta‐analysis

Low circulating total adiponectin, especially its non-high-molecular weight fraction, represents a promising risk factor for colorectal cancer: a meta-analysis

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma

Contact Info

Product

Resources

About